BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32124552)

  • 1. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.
    Renzi S; Michaeli O; Salvador H; Alderete D; Ponce NF; Zapotocky M; Hansford JR; Malalasekera VS; Toledano H; Maguire B; Bouffet E; Ramaswamy V; Baroni LV
    Pediatr Blood Cancer; 2020 May; 67(5):e28228. PubMed ID: 32124552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
    Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis.
    Shi J; Lu D; Gu R; Sun H; Yu L; Pan R; Zhang Y
    Am J Otolaryngol; 2021; 42(6):103148. PubMed ID: 34214711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
    N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.
    Gugel I; Zipfel J; Hartjen P; Kluwe L; Tatagiba M; Mautner VF; Schuhmann MU
    Childs Nerv Syst; 2020 Oct; 36(10):2471-2480. PubMed ID: 32548671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients.
    Fujii M; Ichikawa M; Iwatate K; Bakhit M; Yamada M; Kuromi Y; Sato T; Sakuma J; Saito K
    Neurol Med Chir (Tokyo); 2020 Feb; 60(2):75-82. PubMed ID: 31902875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenesis and molecular pathology of vestibular schwannoma].
    Brodhun M; Stahn V; Harder A
    HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
    Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
    Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center.
    Comes PC; Peyre M; Sanson M; Sterkers O; Bernardeschi D; Kalamarides M
    Laryngoscope; 2021 Jan; 131(1):E98-E107. PubMed ID: 33270257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
    Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
    J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
    Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
    Fisher LM; Doherty JK; Lev MH; Slattery WH
    Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.